KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Obligations AnnualCost Of SalesDistribution Revenue By SegmentDistribution Revenue By Segment AnnualEmployee StatisticsEurope Revenue By CategoryEurope Revenue By Category AnnualFacility Count By RegionGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Income Taxes By RegionInternational Markets Revenue By CategoryInternational Markets Revenue By Category AnnualInventories BreakdownLicensing Arrangements Revenue By SegmentLicensing Arrangements Revenue By Segment AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %North America Revenue By CategoryNorth America Revenue By Category AnnualOpex As A % Of RevenueOPEX SegregationOther Revenue By SegmentOther Revenue By Segment AnnualPharmaceutical Manufacturing SitesProperty, Plant And Equipment By Geographical LocationProperty, Plant & Equipment BreakdownRevenue By Businesss Vertical AnnualRevenue By Businesss Vertical Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By CustomerRevenue By Customer %Revenue By Major ProductsRevenue By Major Products %Revenue By Major Products AnnualRevenue By Major Products Annual %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Sale Of Goods Revenue By SegmentSale Of Goods Revenue By Segment AnnualSegment ProfitSegment Profit AnnualSegment Profit Margin %Segment Profit Margin Annual %Square Footage By RegionWorkforce Headcount By Region
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gross Profit (2016 - 2025)

Historic Gross Profit for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Gross Profit rose 2522.4% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.9 billion, marking a year-over-year increase of 1085.07%. This contributed to the annual value of $8.9 billion for FY2025, which is 1083.83% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Gross Profit stood at $2.7 billion, which was up 2522.4% from $2.3 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Gross Profit high stood at $2.7 billion for Q4 2025, and its period low was $1.6 billion during Q1 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Gross Profit value was $1.9 billion (recorded in 2021), while the average stood at $2.0 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Gross Profit plummeted by 1365.85% in 2022 and then surged by 3644.07% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Gross Profit stood at $2.1 billion in 2021, then fell by 13.66% to $1.8 billion in 2022, then skyrocketed by 36.44% to $2.4 billion in 2023, then fell by 12.17% to $2.1 billion in 2024, then increased by 25.22% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q4 2025, $2.3 billion for Q3 2025, and $2.1 billion during Q2 2025.